Literature DB >> 20371132

Antiproliferative effect of Aurora kinase targeting in mesothelioma.

Stefania Crispi1, Claudia Fagliarone, Annamaria Biroccio, Carmen D'Angelo, Rossella Galati, Ada Sacchi, Bruno Vincenzi, Alfonso Baldi, Alessandra Verdina.   

Abstract

The Aurora proteins are a small family of serine/threonine kinase that function in various stages of mitosis. Current interest in Aurora kinase relates to its role in tumours, and its potential as a therapeutic target. In this work we studied the expression of Aurora kinases A and B and related genes in human mesothelioma tissues and in five mesothelioma cell lines. Moreover, we analyzed the effects of ZM447439 (ZM), an Aurora kinase inhibitor, on cellular growth. Results evidenced an over-expression of Aurora kinase A and related genes in human mesothelioma tissues and an over-expression of Aurora kinases A and B in all cell lines. Moreover, we demonstrated that ZM447439 was able to inhibit cell growth in all cell lines and that this inhibition was due to a specific effect as demonstrated by the reduction in the level of Histone H3 phosphorylation. Our findings support a role of Aurora kinase in mesothelioma and the possibility of using Aurora kinase inhibitors in therapeutic modalities.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20371132     DOI: 10.1016/j.lungcan.2010.03.005

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  6 in total

1.  Update on Aurora Kinase Targeted Therapeutics in Oncology.

Authors:  Myke R Green; Joseph E Woolery; Daruka Mahadevan
Journal:  Expert Opin Drug Discov       Date:  2011-03       Impact factor: 6.098

Review 2.  Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?"

Authors:  Vincenzo Di Noia; Emanuele Vita; Miriam Ferrara; Antonia Strippoli; Michele Basso; Giovanni Schinzari; Alessandra Cassano; Emilio Bria; Carlo Barone; Ettore D'Argento
Journal:  Curr Treat Options Oncol       Date:  2019-02-21

Review 3.  Update on aurora kinase inhibitors in gynecologic malignancies.

Authors:  Xia Tao; Hye S Chon; Siqing Fu; John J Kavanagh; Wei Hu
Journal:  Recent Pat Anticancer Drug Discov       Date:  2008-11       Impact factor: 4.169

4.  Integrative Molecular Characterization of Malignant Pleural Mesothelioma.

Authors:  Julija Hmeljak; Francisco Sanchez-Vega; Katherine A Hoadley; Juliann Shih; Chip Stewart; David Heiman; Patrick Tarpey; Ludmila Danilova; Esther Drill; Ewan A Gibb; Reanne Bowlby; Rupa Kanchi; Hatice U Osmanbeyoglu; Yoshitaka Sekido; Jumpei Takeshita; Yulia Newton; Kiley Graim; Manaswi Gupta; Carl M Gay; Lixia Diao; David L Gibbs; Vesteinn Thorsson; Lisa Iype; Havish Kantheti; David T Severson; Gloria Ravegnini; Patrice Desmeules; Achim A Jungbluth; William D Travis; Sanja Dacic; Lucian R Chirieac; Françoise Galateau-Sallé; Junya Fujimoto; Aliya N Husain; Henrique C Silveira; Valerie W Rusch; Robert C Rintoul; Harvey Pass; Hedy Kindler; Marjorie G Zauderer; David J Kwiatkowski; Raphael Bueno; Anne S Tsao; Jenette Creaney; Tara Lichtenberg; Kristen Leraas; Jay Bowen; Ina Felau; Jean Claude Zenklusen; Rehan Akbani; Andrew D Cherniack; Lauren A Byers; Michael S Noble; Jonathan A Fletcher; A Gordon Robertson; Ronglai Shen; Hiroyuki Aburatani; Bruce W Robinson; Peter Campbell; Marc Ladanyi
Journal:  Cancer Discov       Date:  2018-10-15       Impact factor: 39.397

Review 5.  Curcumin as an Anticancer Agent in Malignant Mesothelioma: A Review.

Authors:  Alfonso Baldi; Antonio De Luca; Patrizia Maiorano; Costantino D'Angelo; Antonio Giordano
Journal:  Int J Mol Sci       Date:  2020-03-07       Impact factor: 5.923

6.  A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma.

Authors:  Carl M Gay; Yanhong Zhou; J Jack Lee; Xi Ming Tang; Wei Lu; Ignacio I Wistuba; Renata Ferrarotto; Don L Gibbons; Bonnie S Glisson; Merrill S Kies; George R Simon; John V Heymach; Anne S Tsao
Journal:  Oncologist       Date:  2020-07-19       Impact factor: 5.837

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.